Suchergebnisse
Radcom (RDCM) Reports Q2 Loss, Lags Revenue Estimates
Radcom (RDCM) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.2. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for
Marex Group PLC (MRX) Tops Q2 Earnings and Revenue Estimates
Marex Group PLC (MRX) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.02 per share a year ago. These
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago. These figures are
Kornit Digital (KRNT) Q2 Earnings and Revenues Beat Estimates
Kornit Digital (KRNT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago
Performance Food Group (PFGC) Q4 Earnings and Revenues Miss Estimates
Performance Food Group (PFGC) came out with quarterly earnings of $1.59 per share, missing the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.55 per share a year ago
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago. These
Similarweb (SMWB) Tops Q2 Earnings and Revenue Estimates
Similarweb (SMWB) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.01 per share a year ago. These figures
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago. These figures
Trimble Navigation (TRMB) Q2 Earnings and Revenues Top Estimates
Trimble Navigation (TRMB) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.71 per share a year ago. These
Kontoor Brands (KTB) Beats Q2 Earnings Estimates
Kontoor Brands (KTB) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.21 per share a year ago. These
ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed
Key Points
- Interested in ASP Isotopes Inc.? Here are five stocks we like better.
- ASP Isotopes is targeting commercial deliveries of Silicon-28, Carbon-14 and Ytterbium-176 in the second half of
Boyd Group Services Q2 Earnings Call Highlights
Key Points
- Interested in Boyd Group Services Inc.? Here are five stocks we like better.
- Strong Q2 growth: Revenue surpassed $1 billion for the first time, rising 30% year over year to $1.013
Annexon Q2 Earnings Call Highlights
Key Points
- Interested in Annexon, Inc.? Here are five stocks we like better.
- Annexon expanded the ARCHER II trial of vonaprument in geographic atrophy to include an independent 24-month
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Acumen Pharmaceuticals, Inc.? Here are five stocks we like better.
- Acumen remains on track to report late-2026 Phase II results from the ALTITUDE-AD study of
Nebius Group (NBIS) Reports Q2 Loss, Tops Revenue Estimates
Nebius Group (NBIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.38 per share a year ago. These figures are
Wall Street Analysts See a 26.15% Upside in TAL Education (TAL): Can the Stock Really Move This High?
TAL Education (TAL) closed the last trading session at $12.16, gaining 18.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Shares of BioCryst Pharmaceuticals (BCRX) have gained 6.2% over the past four weeks to close the last trading session at $10.34, but there could still be a solid upside left in the stock if
Wall Street Analysts See a 66.12% Upside in Kratos (KTOS): Can the Stock Really Move This High?
Kratos (KTOS) closed the last trading session at $63.73, gaining 26.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street